CMND•CMND•Clearmind Medicine secured U.S. Patent No. 12,357,590 covering MEAI-based binge behavior regulators, expanding its portfolio to 19 patent families and 32 granted patents. The new patent strengthens intellectual property protection for its non-hallucinogenic neuroplastogen derivatives targeting alcohol use disorder and other compulsive behaviors.
Clearmind Medicine received U.S. Patent No. 12,357,590, titled "BINGE BEHAVIOR REGULATORS," from the USPTO on June 29, 2026. The patent specifically protects MEAI (5-methoxy-2-aminoindane) and related 2-aminoindan compounds designed to regulate excessive drinking, eating, and other compulsive behaviors.
This new grant builds on the company’s earlier U.S. Patent No. 12,350,242 and brings Clearmind’s portfolio to 19 patent families with 32 granted patents globally. Management highlights this as one of the sector’s most comprehensive patent collections for neuroplastogen-based therapeutics.
Clearmind’s R&D centers on non-hallucinogenic, second-generation neuroplastogen-derived molecules addressing under-treated conditions such as alcohol use disorder and binge-related compulsive disorders. The MEAI-based regulators aim to offer safer alternatives to current treatments by modulating neuroplasticity without psychedelic effects.
By strengthening IP barriers around its lead compounds, Clearmind enhances its competitive positioning ahead of clinical trials and potential partnerships. The company plans to pursue additional patents and opportunistic IP acquisitions to support future regulatory filings and commercialization strategies.
